DDrare: Database of Drug Development for Rare Diseases

Zx008 0.2 and 0.8 mg/kg/day (DrugBank: -)

2 diseases

ID	Disease name (Link within this page)	Number of trials
140	Dorabe syndrome	1
144	Lennox-Gastaut syndrome	1

140. Dorabe syndrome [ 83 clinical trials, 54 drugs, (DrugBank: 13 drugs), 48 drug target genes, 62 drug target pathways]

Searched query = "Dorabe syndrome", "Dravet syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 83 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03467113 (ClinicalTrials.gov)	January 19, 2018	30/1/2018	A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With DS or LGS Currently Taking CBD	An Open-Label Trial to Assess the Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Combination With Cannabidiol, as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome or Lennox-Gastaut Syndrome	Dravet Syndrome;Lennox Gastaut Syndrome	Drug: ZX008 0.2 and 0.8 mg/kg/day	Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.	NULL	Active, not recruiting	2 Years	18 Years	All	25	Phase 1;Phase 2	United States

144. Lennox-Gastaut syndrome [ 80 clinical trials, 63 drugs, (DrugBank: 11 drugs), 49 drug target genes, 59 drug target pathways]

Searched query = "Lennox-Gastaut syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 80 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03467113 (ClinicalTrials.gov)	January 19, 2018	30/1/2018	A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With DS or LGS Currently Taking CBD	An Open-Label Trial to Assess the Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Combination With Cannabidiol, as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome or Lennox-Gastaut Syndrome	Dravet Syndrome;Lennox Gastaut Syndrome	Drug: ZX008 0.2 and 0.8 mg/kg/day	Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.	NULL	Active, not recruiting	2 Years	18 Years	All	25	Phase 1;Phase 2	United States